MCID: OVR012
MIFTS: 54

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 11 53 5 14 16 71
Serous Cystadenoma 11 16
Cystadenoma, Serous 71
Cystadenoma Serous 53

Classifications:



External Ids:

Disease Ontology 11 DOID:5746
NCIt 49 C7978
UMLS 71 C0206709 C0279663

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology: 11 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary: Ovarian Serous Cystadenocarcinoma, also known as serous cystadenoma, is related to serous cystadenocarcinoma and cystadenocarcinoma. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Everolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and endothelial, and related phenotypes are Increased cell migration and Increased cell death in HCT116 cells

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 444)
# Related Disease Score Top Affiliating Genes
1 serous cystadenocarcinoma 31.7 TP53 PPP2R1A PIK3CA NF1 MUC16 HRAS
2 cystadenocarcinoma 31.7 ZNF217 TP53 SERPINA3 NF1 MUC16 FSHR
3 adenoma 31.4 TP53 PIK3CA HRAS BRAF
4 adenocarcinoma 30.9 TP53 PIK3CA HRAS ERBB2 BRAF
5 pancreatic cancer 30.9 TP53 SERPINA3 PIK3CA MUC16 MIR196A1 MIR17
6 cystadenofibroma 30.8 TP53 HRAS
7 endosalpingiosis 30.8 TP53 HRAS BRCA1
8 adenofibroma 30.8 TP53 MUC16 BRAF
9 ovarian cystadenoma 30.8 TP53 MUC16 BRCA1
10 fibroma 30.7 SERPINA3 NF1 MUC16
11 struma ovarii 30.7 NRAS MUC16 BRAF
12 mucinous cystadenocarcinoma 30.7 SERPINA3 MUC16 HRAS
13 pancreatic ductal adenocarcinoma 30.7 TP53 SERPINA3 MIR196A1 MIR17 HRAS
14 uterine corpus endometrial carcinoma 30.6 TP53 PPP2R1A PIK3CA NF1 FBXW7
15 cystadenoma 30.6 SERPINA3 MUC16 HIF1A BRCA1
16 carcinosarcoma 30.6 TP53 PPP2R1A PIK3CA HRAS FBXW7 ERBB2
17 syringocystadenoma papilliferum 30.5 SERPINA3 HRAS BRAF
18 ovarian cancer 30.5 ZNF217 TP53 PPP2R1A PIK3CA MUC16 MIR196A1
19 differentiated thyroid carcinoma 30.5 NRAS HRAS BRAF
20 lobular neoplasia 30.5 TP53 PIK3CA ERBB2 BRCA1
21 fallopian tube carcinoma 30.5 TP53 ERBB2 BRCA1
22 pancreatic ductal carcinoma 30.5 TP53 HRAS ERBB2
23 ovarian benign neoplasm 30.5 TP53 HRAS FSHR BRCA1
24 uterine carcinosarcoma 30.5 TP53 PPP2R1A PIK3CA LRRC56 HRAS FBXW7
25 lipomatosis, multiple 30.5 TP53 SERPINA3 PIK3CA NF1
26 endometriosis 30.5 TP53 MUC16 MIR17 FSHR
27 cholangiocarcinoma 30.4 TP53 PIK3CA ERBB2 BRCA1 BRAF
28 lymphangioma 30.4 TP53 SERPINA3 PIK3CA HRAS BRAF
29 leiomyosarcoma 30.4 TP53 SERPINA3 NF1 MUC16 BRCA1
30 pancreatic adenocarcinoma 30.3 TP53 PIK3CA LRRC56 HRAS ERBB2 BRAF
31 kidney cancer 30.3 TP53 PIK3CA MIR17 HIF1A
32 bile duct cancer 30.3 TP53 PIK3CA MIR196A1 MIR17 HRAS ERBB2
33 endometrial cancer 30.1 TP53 PIK3CA NRAS NF1 MUC16 HRAS
34 renal cell carcinoma, nonpapillary 29.9 TP53 PIK3CA NRAS MIR196A1 MIR17 HRAS
35 lung cancer susceptibility 3 29.6 TP53 PPP2R1A PIK3CA NRAS MUC16 MIR196A1
36 pancreatic serous cystadenoma 11.7
37 serous cystadenoma of childhood 11.3
38 appendix adenocarcinoma 10.9
39 islet cell tumor 10.5
40 childhood leptomeningeal melanoma 10.5 NRAS HRAS
41 microcystic adenoma 10.5
42 cutaneous-skeletal hypophosphatemia syndrome 10.5 LRRC56 HRAS
43 esophagus small cell carcinoma 10.5 PIK3CA ERBB2
44 basaloid lung carcinoma 10.5 TP53 BRCA1
45 spitz nevus 10.5 HRAS BRAF
46 nevus of ota 10.5 TP53 BRAF
47 neuroendocrine tumor 10.5
48 cervical adenocarcinoma 10.5 TP53 MUC16 BRAF
49 melphalan allergy 10.5 NRAS BRAF
50 vaginal cancer 10.5 TP53 HRAS BRCA1

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell migration GR00055-A-1 8.96 NF1
2 Increased cell migration GR00055-A-3 8.96 NF1
3 Increased cell death in HCT116 cells GR00103-A-0 8.8 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
2 neoplasm MP:0002006 10.39 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
3 growth/size/body region MP:0005378 10.39 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
4 normal MP:0002873 10.27 BRAF BRCA1 ERBB2 FBXW7 HIF1A HRAS
5 endocrine/exocrine gland MP:0005379 10.27 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
6 cardiovascular system MP:0005385 10.22 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
7 digestive/alimentary MP:0005381 10.2 B2M BRAF BRCA1 ERBB2 FBXW7 HIF1A
8 muscle MP:0005369 10.16 BRAF BRCA1 ERBB2 HIF1A HRAS NF1
9 limbs/digits/tail MP:0005371 10.15 BRAF BRCA1 ERBB2 FSHR HIF1A NF1
10 immune system MP:0005387 10.15 B2M BRAF BRCA1 FBXW7 FSHR HIF1A
11 embryo MP:0005380 10.13 BRAF BRCA1 ERBB2 FBXW7 HIF1A NF1
12 adipose tissue MP:0005375 10.08 BRAF BRCA1 FSHR HIF1A PIK3CA TP53
13 craniofacial MP:0005382 10.03 BRAF ERBB2 FBXW7 HIF1A HRAS NF1
14 reproductive system MP:0005389 10 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
15 respiratory system MP:0005388 9.97 BRAF BRCA1 ERBB2 FBXW7 HIF1A HRAS
16 skeleton MP:0005390 9.9 BRAF BRCA1 ERBB2 FSHR HIF1A HRAS
17 mortality/aging MP:0010768 9.86 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR
18 integument MP:0010771 9.47 B2M BRAF BRCA1 ERBB2 FBXW7 FSHR

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
2
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
3
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
4
Sargramostim Approved, Investigational Phase 2 123774-72-1
5
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
6
Belinostat Approved, Investigational Phase 2 414864-00-9, 866323-14-0 53437714 6918638
7
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
8
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
9
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
10
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
11
Lenograstim Approved, Investigational Phase 2 135968-09-1
12
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
13
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
14
Molgramostim Investigational Phase 2 99283-10-0
15
MK-1775 Investigational Phase 2 955365-80-7 24856436
16
Spartalizumab Investigational Phase 2 1935694-88-4
17 Estrogens Phase 2
18 Estrogen Receptor Antagonists Phase 2
19 Estrogen Antagonists Phase 2
20 Aromatase Inhibitors Phase 2
21 Protein Kinase Inhibitors Phase 2
22 Histone Deacetylase Inhibitors Phase 2
23 Immunoglobulins Phase 1, Phase 2
24 Antibodies Phase 1, Phase 2
25 Antiviral Agents Phase 2
26 Anti-Infective Agents Phase 2
27 Antimetabolites Phase 2
28 Immune Checkpoint Inhibitors Phase 2
29 Hypoglycemic Agents Phase 2
30 Immunosuppressive Agents Phase 2
31 Immunologic Factors Phase 2
32 Albumin-Bound Paclitaxel Phase 2
33 Antimitotic Agents Phase 2
34 Tubulin Modulators Phase 2
35 topoisomerase I inhibitors Phase 2
36 Antirheumatic Agents Phase 2
37 Alkylating Agents Phase 2
38 Antineoplastic Agents, Alkylating Phase 2
39 Adjuvants, Immunologic Phase 2
40
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
41
Denileukin diftitox Approved, Investigational Phase 1 173146-27-5
42
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
43
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
44
Bevacizumab Approved, Investigational Phase 1 216974-75-3 135329020
45
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
46
Paclitaxel poliglumex Experimental, Investigational Phase 1 263351-82-2
47
Veliparib Investigational Phase 1 912444-00-9 11960529
48 Interleukin-2 Phase 1
49 Analgesics, Non-Narcotic Phase 1
50 Analgesics Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
2 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
3 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
4 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
5 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
6 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
7 A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP Recruiting NCT05074472 Phase 1, Phase 2 ZB131
8 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
9 Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff Active, not recruiting NCT04802876 Phase 2 Spartalizumab
10 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer Suspended NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
11 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
12 A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
13 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00079430 Phase 1 paclitaxel;carboplatin
14 A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
15 PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
16 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
17 Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer Completed NCT00357448 Phase 1
18 A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
19 A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
20 A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
21 A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
22 A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
23 The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq Withdrawn NCT02050009 Phase 1 metformin hydrochloride;carboplatin;paclitaxel
24 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Unknown status NCT03884179
25 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
26 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
27 A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas Completed NCT02523170
28 A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer Active, not recruiting NCT02111941 Early Phase 1
29 Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors. Active, not recruiting NCT03305146
30 Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy Terminated NCT01275664 Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch
31 Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions Terminated NCT02494388
32 A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

Organs/tissues related to Ovarian Serous Cystadenocarcinoma:

MalaCards : Ovary, Pancreas, Endothelial, Spleen, Prostate, Testis, Breast

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show top 50) (show all 1113)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. 53 62
17309670 2007
3
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. 53 62
17160949 2006
4
Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease. 53 62
14627339 2003
5
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 53 62
1506732 1992
6
Predictors of adverse events after endoscopic ultrasound-guided through-the-needle biopsy of pancreatic cysts: a recursive partitioning analysis. 62
35451041 2022
7
Serous Cystadenoma of the Pancreas Showing Increased Uptake on 68 Ga-FAPI PET/CT. 62
35868001 2022
8
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. 62
35916971 2022
9
Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on 68Ga-DOTATOC PET/CT. 62
36280584 2022
10
Accuracy and agreement of a large panel of endosonographers for endomicroscopy-guided virtual biopsy of pancreatic cystic lesions. 62
36089484 2022
11
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
12
Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. 62
36369472 2022
13
Laparoscopy ıs a defınıtıve dıagnostıc method for auto-amputated ovary ın ınfants. 62
35964259 2022
14
Pancreatic solid serous cystadenoma in the pancreatic head with increasing tracer uptake at 68-GaDOTA-peptide positron emission tomography: A case report. 62
36411164 2022
15
Classification prediction of pancreatic cystic neoplasms based on radiomics deep learning models. 62
36447168 2022
16
A Rare Case of Collision Tumours of the Ovary: An Ovarian Serous Cystadenoma Coexisting with Fibrothecoma. 62
36428899 2022
17
Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance. 62
35920183 2022
18
Massive pancreatic serous cystadenomas raise important questions regarding surgical management of incidental pancreatic cystic lesions: a report of two cases. 62
36388676 2022
19
Comparison of immunohistochemical characteristics of endometriomas with non-endometriotic benign ovarian cysts. 62
36314331 2022
20
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. 62
36255654 2022
21
Incidental discovery of a giant ovarian cystadenoma. 62
36268316 2022
22
[Colloid Carcinoma of the pancreas and synchronous gastrointestinal stromal tumour of stomach. A case report and review of the literature]. 62
36154734 2022
23
A rare case of pancreatic macrocystic serous cystadenoma in an adolescent: a case report and literature review. 62
36259129 2022
24
High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses. 62
36330402 2022
25
Surgical challenges during open pancreaticoduodenectomy in a patient with situs inversus totalis: A rare case report and literature review. 62
36268427 2022
26
Microcystic serous cystadenoma mimicking pancreatic neuroendocrine neoplasm: report of a resected case with preoperative diagnostic difficulty and review of the literature. 62
36178634 2022
27
Classification of endoscopic ultrasound guided fine needle aspiration cytology of pancreatic space occupying lesions by Papanicolaou Society of Cytopathology System: A five year study. 62
36165589 2022
28
Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous cystic lesions. 62
35140056 2022
29
Ectopic Ovarian Serous Cystadenoma Mimicking Hydrosalpinx. 62
35680031 2022
30
Laparoscopic surgery for fallopian tube torsion due to benign tumour in the third trimester of pregnancy: a case report and literature review. 62
35929982 2022
31
Hexokinase 2 promoted cell motility and proliferation by activating Akt1/p-Akt1 in human ovarian cancer cells. 62
35953860 2022
32
Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma. 62
35954427 2022
33
Pancancer Analysis of the Oncogenic and Prognostic Role of NOL7: A Potential Target for Carcinogenesis and Survival. 62
36077008 2022
34
Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs) Harboring Oncogenic Potential and Is Markedly Upregulated in Hepatocellular Carcinoma. 62
36009801 2022
35
Rare case of testosterone producing serous cystadenoma. 62
35991491 2022
36
Differential epithelial and stromal LGR5 expression in ovarian carcinogenesis. 62
35778589 2022
37
Serous cystadenoma of the tunica testis: A case of malignancy mimicry. 62
35300352 2022
38
Solid serous cystadenoma of the pancreas: A rare tumor with challenging differential diagnosis. 62
34256995 2022
39
Pancreatic serous cystadenoma with a positive octreotide scan. 62
35122809 2022
40
Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma. 62
35285286 2022
41
Molecular features of pancreaticobiliary neoplasms: Implications for diagnosis, prognostication, and therapy selection. 62
35751521 2022
42
Expression Profiles of ID and E2A in Ovarian Cancer and Suppression of Ovarian Cancer by the E2A Isoform E47. 62
35740568 2022
43
The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis. 62
35628603 2022
44
Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease-related lesions. 62
35196526 2022
45
Pancreatic serous cystadenocarcinoma diagnosed with liver metastasis at 7 years after the resection of the primary serous neoplastic lesion. 62
35013932 2022
46
Cholesterolosis of ovary associated with benign serous cystadenoma. 62
35435409 2022
47
[Neonatal bilateral ovarian cystadenoma: Conservative or surgical treatment?] 62
35735305 2022
48
Ovarian Serous Cystadenoma Presents As Bladder Issues in 23-Year-Old Female: A Case Report. 62
35281584 2022
49
Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas. 62
35350224 2022
50
Risk of malignancy associated with diagnostic categories of the proposed World Health Organization International System for Reporting Pancreaticobiliary Cytopathology. 62
34623767 2022

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

5 (show top 50) (show all 225)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ERBB2 NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe) SNV Likely Pathogenic
376189 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
2 B2M NM_004048.4(B2M):c.1A>G (p.Met1Val) SNV Likely Pathogenic
376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
3 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely Pathogenic
69961 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
4 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely Pathogenic
376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
5 B2M NM_004048.4(B2M):c.3G>A (p.Met1Ile) SNV Likely Pathogenic
376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
6 PPP2R1A NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly) SNV Likely Pathogenic
376507 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
7 FBXW7 NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His) SNV Likely Pathogenic
376425 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
8 B2M NM_004048.4(B2M):c.2T>C (p.Met1Thr) SNV Likely Pathogenic
376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
9 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
10 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu) SNV Likely Pathogenic
376424 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
11 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely Pathogenic
375874 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
12 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely Pathogenic
376423 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
13 PPP2R1A NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp) SNV Likely Pathogenic
376505 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
14 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
15 BRAF NM_004333.6(BRAF):c.1742A>G (p.Asn581Ser) SNV Likely Pathogenic
177776 rs121913370 GRCh37: 7:140453193-140453193
GRCh38: 7:140753393-140753393
16 BRAF NM_004333.6(BRAF):c.1741A>C (p.Asn581His) SNV Likely Pathogenic
55794 rs180177040 GRCh37: 7:140453987-140453987
GRCh38: 7:140754187-140754187
17 B2M NM_004048.4(B2M):c.2T>G (p.Met1Arg) SNV Likely Pathogenic
376372 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
18 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely Pathogenic
280409 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
19 BRAF NM_004333.6(BRAF):c.1742A>C (p.Asn581Thr) SNV Likely Pathogenic
376376 rs121913370 GRCh37: 7:140453193-140453193
GRCh38: 7:140753393-140753393
20 B2M NM_004048.4(B2M):c.1A>T (p.Met1Leu) SNV Likely Pathogenic
376370 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
21 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
22 PPP2R1A NM_014225.6(PPP2R1A):c.548G>A (p.Arg183Gln) SNV Likely Pathogenic
376506 rs1057519947 GRCh37: 19:52715983-52715983
GRCh38: 19:52212730-52212730
23 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely Pathogenic
376416 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
24 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely Pathogenic
376414 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
25 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely Pathogenic
376418 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
26 PIK3CA NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln) SNV Likely Pathogenic
376481 rs1057519932 GRCh37: 3:178952086-178952086
GRCh38: 3:179234298-179234298
27 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely Pathogenic
13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
28 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely Pathogenic
376415 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
29 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely Pathogenic
376417 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
30 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
31 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
32 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Likely Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
33 ERBB2 NM_004448.4(ERBB2):c.929C>A (p.Ser310Tyr) SNV Likely Pathogenic
376188 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
34 TP53 NM_000546.6(TP53):c.432G>T (p.Gln144His) SNV Likely Pathogenic
376648 rs786201419 GRCh37: 17:7578498-7578498
GRCh38: 17:7675180-7675180
35 TP53 NM_000546.6(TP53):c.839G>T (p.Arg280Ile) SNV Likely Pathogenic
161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
36 TP53 NM_000546.6(TP53):c.518T>C (p.Val173Ala) SNV Likely Pathogenic
376017 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
37 TP53 NM_000546.6(TP53):c.809T>G (p.Phe270Cys) SNV Likely Pathogenic
376597 rs1057519986 GRCh37: 17:7577129-7577129
GRCh38: 17:7673811-7673811
38 TP53 NM_000546.6(TP53):c.815T>A (p.Val272Glu) SNV Likely Pathogenic
376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
39 TP53 NM_000546.6(TP53):c.452C>G (p.Pro151Arg) SNV Likely Pathogenic
376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
40 TP53 NM_000546.6(TP53):c.645T>G (p.Ser215Arg) SNV Likely Pathogenic
376661 rs1057520001 GRCh37: 17:7578204-7578204
GRCh38: 17:7674886-7674886
41 TP53 NM_000546.6(TP53):c.659A>C (p.Tyr220Ser) SNV Likely Pathogenic
12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
42 TP53 NM_000546.6(TP53):c.730G>C (p.Gly244Arg) SNV Likely Pathogenic
376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
43 TP53 NM_000546.6(TP53):c.857A>T (p.Glu286Val) SNV Likely Pathogenic
376592 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
44 TP53 NM_000546.6(TP53):c.721T>C (p.Ser241Pro) SNV Likely Pathogenic
376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
45 TP53 NM_000546.6(TP53):c.658T>G (p.Tyr220Asp) SNV Likely Pathogenic
376689 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
46 TP53 NM_000546.6(TP53):c.644G>A (p.Ser215Asn) SNV Likely Pathogenic
376662 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
47 TP53 NM_000546.6(TP53):c.452C>A (p.Pro151His) SNV Likely Pathogenic
376639 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
48 TP53 NM_000546.6(TP53):c.824G>T (p.Cys275Phe) SNV Likely Pathogenic
376582 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
49 TP53 NM_000546.6(TP53):c.746G>T (p.Arg249Met) SNV Likely Pathogenic
376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
50 TP53 NM_000546.6(TP53):c.614A>T (p.Tyr205Phe) SNV Likely Pathogenic
376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TP53 PPP2R1A NRAS NF1 HRAS HIF1A
2
Show member pathways
13.71 TP53 PPP2R1A PIK3CA NRAS NF1 MUC16
3 13.67 ZNF217 TP53 PPP2R1A PIK3CA NRAS NF1
4
Show member pathways
13.56 TP53 PPP2R1A PIK3CA NRAS HRAS ERBB2
5
Show member pathways
13.55 PPP2R1A PIK3CA NRAS HRAS HIF1A FBXW7
6
Show member pathways
13.49 TP53 PIK3CA NRAS NF1 HRAS ERBB2
7
Show member pathways
13.37 PPP2R1A PIK3CA NRAS NF1 HRAS FBXW7
8
Show member pathways
13.34 TP53 PPP2R1A PIK3CA NRAS HRAS HIF1A
9
Show member pathways
12.92 BRCA1 HIF1A HRAS NRAS PIK3CA PPP2R1A
10
Show member pathways
12.9 PPP2R1A PIK3CA NRAS HRAS BRAF
11
Show member pathways
12.87 PIK3CA NRAS HRAS ERBB2 BRAF
12
Show member pathways
12.86 TP53 PIK3CA NRAS HRAS BRAF
13 12.79 BRAF ERBB2 HIF1A HRAS NRAS PIK3CA
14 12.71 TP53 PIK3CA HRAS HIF1A BRCA1
15
Show member pathways
12.68 BRAF HRAS NRAS PPP2R1A TP53
16
Show member pathways
12.64 TP53 PPP2R1A PIK3CA NRAS HRAS
17
Show member pathways
12.6 ERBB2 HRAS NRAS PIK3CA TP53
18
Show member pathways
12.59 PPP2R1A PIK3CA NRAS HRAS BRAF
19
Show member pathways
12.56 PPP2R1A PIK3CA NRAS HRAS BRAF
20
Show member pathways
12.53 TP53 PIK3CA NRAS NF1 HRAS ERBB2
21
Show member pathways
12.45 TP53 PIK3CA HRAS ERBB2 BRAF
22
Show member pathways
12.43 TP53 PIK3CA NRAS HRAS ERBB2
23
Show member pathways
12.41 BRAF ERBB2 HRAS NRAS PIK3CA
24 12.4 TP53 NRAS NF1 HRAS BRAF
25
Show member pathways
12.39 BRAF BRCA1 HRAS NF1 PIK3CA
26
Show member pathways
12.37 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
27 12.31 PIK3CA HRAS ERBB2 BRAF
28 12.27 PIK3CA NRAS NF1 HRAS
29
Show member pathways
12.26 ERBB2 HRAS NRAS PIK3CA
30
Show member pathways
12.25 PPP2R1A PIK3CA NRAS HRAS BRAF
31 12.2 TP53 PIK3CA HRAS HIF1A
32
Show member pathways
12.2 TP53 NRAS HRAS BRAF
33
Show member pathways
12.17 NRAS HRAS HIF1A ERBB2
34
Show member pathways
12.17 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
35
Show member pathways
12.16 NRAS NF1 HRAS BRAF
36 12.16 TP53 NF1 BRCA1 BRAF
37
Show member pathways
12.13 TP53 PIK3CA NRAS HRAS ERBB2 BRCA1
38
Show member pathways
12.08 ERBB2 HRAS NRAS PIK3CA
39
Show member pathways
12.05 PIK3CA NRAS HRAS ERBB2
40
Show member pathways
12.02 TP53 PIK3CA ERBB2 BRAF
41
Show member pathways
11.98 PIK3CA NRAS HRAS ERBB2
42
Show member pathways
11.91 PIK3CA NRAS HRAS
43
Show member pathways
11.89 PIK3CA NRAS HRAS
44 11.88 BRAF HRAS NF1 NRAS PPP2R1A
45
Show member pathways
11.86 HRAS NRAS PIK3CA
46
Show member pathways
11.85 PIK3CA NRAS HRAS
47 11.82 TP53 PIK3CA HRAS
48
Show member pathways
11.8 PIK3CA NRAS HRAS BRAF
49
Show member pathways
11.79 TP53 PIK3CA NRAS HRAS
50
Show member pathways
11.76 PIK3CA NRAS HRAS B2M

GO Terms for Ovarian Serous Cystadenocarcinoma

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 10.14 NRAS NF1 HRAS BRAF
2 negative regulation of neuron apoptotic process GO:0043524 10.09 PIK3CA HRAS HIF1A BRAF
3 visual learning GO:0008542 10.03 NF1 HIF1A BRAF
4 Ras protein signal transduction GO:0007265 10.03 HRAS NF1 NRAS TP53
5 phosphatidylinositol 3-kinase signaling GO:0014065 10 ERBB2 NF1 PIK3CA
6 positive regulation of gene expression GO:0010628 10 BRAF BRCA1 ERBB2 HIF1A HRAS MIR17
7 T cell differentiation in thymus GO:0033077 9.99 TP53 BRAF B2M
8 neuroblast proliferation GO:0007405 9.95 TP53 NF1 HIF1A
9 fibroblast proliferation GO:0048144 9.93 TP53 NF1 HRAS
10 neuron apoptotic process GO:0051402 9.92 TP53 NF1 HRAS HIF1A
11 negative regulation of reactive oxygen species metabolic process GO:2000378 9.88 TP53 HIF1A BRCA1
12 negative regulation of gene expression GO:0010629 9.85 TP53 PIK3CA MIR17 HRAS HIF1A FBXW7
13 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.8 TP53 HIF1A
14 vasculature development GO:0001944 9.77 PIK3CA HIF1A FBXW7
15 regulation of cell population proliferation GO:0042127 9.23 TP53 NF1 HRAS HIF1A ERBB2 BRAF
16 regulation of thymocyte apoptotic process GO:0070243 8.96 TP53 HIF1A

Sources for Ovarian Serous Cystadenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....